Differential effects of obesity with and without hyperinsulinemia on plasma lipoprotein(a) concentrations in men

Metabolism ◽  
2001 ◽  
Vol 50 (2) ◽  
pp. 178-183 ◽  
Author(s):  
Carlos Posadas-Romero ◽  
Antonio Hernández-Ono ◽  
José Zamora-González ◽  
Guillermo Cardoso-Saldaña ◽  
Liria Yamamoto-Kimura ◽  
...  
Keyword(s):  
Plasma Lipoprotein ◽  
Differential Effects ◽  
Lipoprotein A

Plasma Lipoprotein(a) [LP(a)] Concentrations and Apoprotein(a) [APO(a)] Isoforms in Chronic Renal Disease

1997 ◽  
Vol 93 (s37) ◽  
pp. 13P-13P
Author(s):  
DA Reaveley ◽  
M Misra ◽  
N Al-Khalaf ◽  
E Brown ◽  
J Alaghband-Zadeh
Keyword(s):  
Renal Disease ◽  
Chronic Renal Disease ◽  
Plasma Lipoprotein ◽  
Lipoprotein A

scholarly journals Relationship of Plasma ApolipoproteinC3 with Plasma Lipoprotein(a)

2021 ◽  
Vol 35 (S1) ◽  
Author(s):  
Anastasiya Matveyenko ◽  
Nelsa Matienzo ◽  
Tiffany Thomas ◽  
Sekhar Ramakrishnan ◽  
Heather Seid ◽  
...  
Keyword(s):  
Plasma Lipoprotein ◽  
Lipoprotein A ◽  
Relationship Of

scholarly journals Distribution of Lipoprotein (a) in Plasma Lipoprotein Subfractions

1995 ◽  
Vol 23 (4-5) ◽  
pp. 255-261
Author(s):  
Hiroshi YAMAGUCHI ◽  
Toshio KOBAYASHI ◽  
Hideki OZAWA ◽  
Hiroya SAKANE ◽  
Kumi OSHIMA ◽  
...  
Keyword(s):  
Plasma Lipoprotein ◽  
Lipoprotein Subfractions ◽  
Lipoprotein A

Plasma lipoprotein(a) levels in patients with homozygous autosomal dominant hypercholesterolemia

2017 ◽  
Vol 11 (2) ◽  
pp. 507-514 ◽  
Author(s):  
Barbara Sjouke ◽  
Reyhana Yahya ◽  
Michael W.T. Tanck ◽  
Joep C. Defesche ◽  
Jacqueline de Graaf ◽  
...  
Keyword(s):  
Autosomal Dominant ◽  
Plasma Lipoprotein ◽  
Lipoprotein A

Effect of extended-release niacin on plasma lipoprotein(a) levels: A systematic review and meta-analysis of randomized placebo-controlled trials

Metabolism ◽  
2016 ◽  
Vol 65 (11) ◽  
pp. 1664-1678 ◽  
Author(s):  
Amirhosssein Sahebkar ◽  
Željko Reiner ◽  
Luis E. Simental-Mendía ◽  
Gianna Ferretti ◽  
Arrigo F.G. Cicero
Keyword(s):  
Systematic Review ◽  
Extended Release ◽  
Meta Analysis ◽  
Plasma Lipoprotein ◽  
Controlled Trials ◽  
Lipoprotein A

Abstract 329: Mechanism by Which Anacetrapib Lowers Plasma Lipoprotein (a) Concentration

2012 ◽  
Vol 32 (suppl_1) ◽  
Author(s):  
Tiffany A Thomas ◽  
Haihong Zhou ◽  
Thomas Roddy ◽  
Stephen Previs ◽  
Michael Lassman ◽  
...  
Keyword(s):  
Plasma Lipoprotein ◽  
Entire Group ◽  
Fixed Sequence ◽  
Lipoprotein A ◽  
Synthetic Rate ◽  
Period 2 ◽  
Catabolic Rate ◽  
Fractional Synthetic Rate ◽  
Cetp Inhibitor ◽  
Sequence Study

Objective: Anacetrapib, a CETP inhibitor, was previously shown to decrease plasma lipoprotein (a) [Lp(a)] levels by 35-40% in subjects also taking a statin. Thus, anacetrapib is an efficacious Lp(a)-lowering agent. The goal of this study was to define the mechanism by which anacetrapib lowers plasma Lp(a) levels. Methods: 39 moderately hyperlipidemic volunteers were enrolled in a fixed-sequence study, in which 75% were on atorvastatin 20mg/day, plus placebo for four weeks (period 1), and then atorvastatin plus anacetrapib (100 mg/day) for 8 weeks (period 2). The other 25% of the subjects received double placebo for four weeks, and then placebo plus anacetrapib for 8 weeks. Turnover studies using D3-leucine were performed at the end of each period. The present analysis utilized samples from a subset of subjects (n=12) who had plasma Lp(a) levels greater than 10 nM at the end of period 1 and had a greater than 10% reduction in Lp(a) by the end of period 2. The fractional synthetic rate (FSR:equal to fractional catabolic rate at steady state) of mature Lp(a), isolated from a D:1.019-1.21 g/ml density interval, was determined from the enrichment of a leucine-containing peptide specific to apo(a). The production rate (PR) of mature Lp(a) was calculated from the FSR and the Lp(a) pool size. To date, we have calculated the FSR and PR in 4 participants. Results: Baseline Lp(a) mean levels were 45.7 ± 6.3nM in the entire group and 56.5 ± 33.6nM in the 12 qualifying subjects. Anacetrapib lowered Lp(a) by 43 ± 22% in the 12 subjects and 21 ±12% in the 4 subjects with turnover data. In these 4 subjects, the reduction in mature Lp(a) was associated with a 24% reduction in FSR and a 41% reduction in PR. Lp(a) kinetics analyses of the remaining 8 subjects are in progress. Conclusion: These preliminary results suggest that anacetrapib decreases Lp(a) levels by significantly decreasing the production of mature Lp(a). Additional analyses are planned to determine if the reduced production of Lp(a) results from decreased entry of Lp(a) into plasma or reduced conversion of a precursor form to the mature Lp(a).

scholarly journals Plasma Lipoprotein (a) Levels in Men and Women Consuming Diets Enriched in Saturated, Cis -, or Trans -Monounsaturated Fatty Acids

1997 ◽  
Vol 17 (9) ◽  
pp. 1657-1661 ◽  
Author(s):  
Beverly A. Clevidence ◽  
Joseph T. Judd ◽  
Ernst J. Schaefer ◽  
Jennifer L. Jenner ◽  
Alice H. Lichtenstein ◽  
...  
Keyword(s):  
Fatty Acids ◽  
Monounsaturated Fatty Acids ◽  
Plasma Lipoprotein ◽  
Men And Women ◽  
Lipoprotein A

scholarly journals Pattern of plasma lipoprotein (a) in Sudanese patients with coronary artery disease

2008 ◽  
Vol 2 (3) ◽  
Author(s):  
M E Farah ◽  
K Eltahir ◽  
HHM A Elhassan ◽  
MOEH Gadour ◽  
M S Alkhaleefa
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Plasma Lipoprotein ◽  
Lipoprotein A ◽  
Artery Disease
Sign in / Sign up

Export Citation Format

Share Document